AstraZeneca Vietnam in coordination with the Vietnam Cancer Society has just organized a scientific conference with the theme "New Era in Lung Cancer Treatment: Realizing the goal of radicalization with targeted therapy and immunity" on two days, April 11 in Hanoi and April 12 in Ho Chi Minh City.
Gathering leading domestic and international experts, the conference brings the latest advances in lung cancer treatment, and introduces new treatment solutions approved by the Ministry of Health, opening up more opportunities to access advanced solutions for patients in Vietnam.
This is an important step towards realizing the goal of radicalization for lung cancer patients, in the context that this disease is one of the leading causes of death in Vietnam, with more than 22,000 deaths each year (according to Globocan 2022).
In particular, the group of patients with localized small cell lung cancer and non-small cell lung cancer in stage III who cannot be operated on are currently facing a poor prognosis and high recurrence rates after chemotherapy and radiation therapy, creating a large economic burden for families and society.
At the conference, international and domestic experts emphasized the role of post-radiation and chemotherapy consolidation treatment strategies through two breakthrough studies: ADRIATIC and LAURA.
Specifically, immunotherapy with Durvalumab helps small cell lung cancer patients achieve a midlife of nearly 56 months. Meanwhile, targeted therapy with Osimertinib helps extend the progression-free lifespan to 39.1 months (compared to 5.6 months in the placebo group) for patients with EGFR mutations.
Mr. Atul Tandon - Chairman cum General Director of AstraZeneca Vietnam - affirmed that the unit will continue to cooperate with the medical community and partners in the health system to bring advanced medical applications, contributing to narrowing the gap in access and towards sustainable improvement for cancer patients in Vietnam.
